Way to reduce rituximab effect found
Each year, 3,500 Taiwanese get lymphoma, and 60% of them are placed on rituximab chemotherapy.
Rituximab activates hepatitis B virus and leads to acute hepatitis and acute liver failure.
Proactive intake of preventative hepatitis B antiviral drugs before administration of rituximab for lymphoma reduces the 55% revival rate due to rituximab therapy down to 2.5% recurrence.
At present, there are 1,234 lymphoma patients who are hepatitis B sufferers.
This report can be found in the June 2019 edition of the Journal of the Formosan Medical Association.